The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Open accessAbstract
BACKGROUND: Interleukin-31 may play a role in the pathobiologic mechanism of atopic dermatitis and pruritus. We wanted to assess the efficacy and safety of nemolizumab (CIM331), a humanized antibody against interleukin-31 receptor A, in the treatment of atopic dermatitis. METHODS: In this phase 2, randomized, double-blind, placebo-controlled, 12-week trial, we assigned adults with moderate-to-severe atopic dermatitis that was inadequately controlled by topical treatments to receive subcutaneous nemolizumab (at a dose of 0.1 mg, 0.5 mg, or 2.0 mg per kilogram of body weight) or placebo every 4 weeks or an exploratory dose of 2.0 mg of nemolizumab per kilogram every 8 weeks. The primary end point was the percentage improvement from baseline in the score on the pruritus visual-analogue scale (on which a negative change indicates improvement) at week 12. Secondary end points included changes in the score on the Eczema Area and Severity Index (EASI, on which a negative change indicates improvement), and body-surface area of atopic dermatitis. RESULTS: Of 264 patients who underwent randomization, 216 (82%) completed the study. At week 12, among the patients who received nemolizumab every 4 weeks, changes on the pruritus visual-analogue scale were -43.7% in the 0.1-mg group, -59.8% in the 0.5-mg group, and -63.1% in the 2.0-mg group, versus -20.9% in the placebo group (P<0.01 for all comparisons). Changes on the EASI were -23.0%, -42.3%, and -40.9%, respectively, in the nemolizumab groups, versus -26.6% in the placebo group. Respective changes in body-surface area affected by atopic dermatitis were -7.5%, -20.0%, and -19.4% with nemolizumab, versus -15.7% with placebo. Among the patients receiving nemolizumab every 4 weeks, treatment discontinuations occurred in 9 of 53 patients (17%) in the 0.1-mg group, in 9 of 54 (17%) in the 0.5-mg group, and in 7 of 52 (13%) in the 2.0-mg group, versus in 9 of 53 (17%) in the placebo group. CONCLUSIONS: In this phase 2 trial, nemolizumab at all monthly doses significantly improved pruritus in patients with moderate-to-severe atopic dermatitis, which showed the efficacy of targeting interleukin-31 receptor A. The limited size and length of the trial preclude conclusions regarding adverse events. (Funded by Chugai Pharmaceutical; XCIMA ClinicalTrials.gov number, NCT01986933 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a phase IIa study, the anti-IL-31Rα antibody nemolizumab led to a significant decrease in the pruritus sensation”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [189]
In the citing paper
“but the overall clinical inflammation as evaluated by the body surface area (BSA), EASI and IGA scorings did not improve significantly at this time point189.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [189]
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586 · cited 1×
“Japan 16 (30) 16 (30) 16 (30) 16 (31) 15 (29)”
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Bieber, T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra074081 · Cited by 1,780
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224 · cited 3×
“Not related to atopic dermatitis 1 (2) 1 (2) 0 1 (2) 1 (2)”
Self-citationThe eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Self-citationIL-31: A new link between T cells and pruritus in atopic skin inflammation
Sonkoly, E., Muller, A., Lauerma, A. I., Pivarcsi, A., Soto, H., Kemeny, L., Alenius, H., Dieu-Nosjean, M.-C., Meller, S., Rieker, J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.10.033 · Cited by 1,005
Self-citationGittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981 · cited 1×
“4 22 (42) 18 (34) 25 (46) 25 (48) 22 (42)”
Guidelines of care for the management of atopic dermatitis
Sidbury, R., Davis, D. M., Cohen, D. E., Cordoro, K. M., Berger, T. G., Bergman, J. N., Chamlin, S. L., Cooper, K. D., Feldman, S. R., Hanifin, J. M., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.030 · Cited by 885 · cited 1×
“(%)† 8 (15) 9 (17) 6 (11) 5 (10) 7 (13)”
Self-citationCevikbas, F., Wang, X., Akiyama, T., Kempkes, C., Savinko, T., Antal, A., Kukova, G., Buhl, T., Ikoma, A., Buddenkotte, J., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.10.048 · Cited by 804 · cited 2×
“(%)† 7 (13) 11 (21) 10 (19) 11 (21) 9 (17)”
Guidelines for treatment of atopic eczema (atopic dermatitis) Part I
Ring, J., Alomar, A., Bieber, T., Deleuran, M., Fink‐Wagner, A., Gelmetti, C., Gieler, U., Lipozencic, J., Luger, T., Oranje, A. P., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04635.x · Cited by 683
Self-citation
Research works printed but not linked: 2
- Oyama S, Exp Dermatol
- Lichstein KL, 2006, Sleep, 29, 232
Cited by
Langan, S. M., Irvine, A. D., & Weidinger, S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31286-1 · Cited by 1,852
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0001-z · Cited by 1,549
Self-citationWollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
Self-citationRecent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102
Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch
Oetjen, L. K., Mack, M. R., Feng, J., Whelan, T. M., Niu, H., Guo, C. J., Chen, S., Trier, A. M., Xu, A. Z., Tripathi, S. V., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.006 · Cited by 1,092
Metadata
- Authors
- Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., Stewart, J., & Kabashima, K.
- Affiliations
- Jagiellonian University (PL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-03-02
- Volume
- 376
- Issue
- 9
- Pages
- 826-835
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2593200577
- Cited by
- 592
- References
- 40
- Citations by year
- 2026: 30 · 2025: 34 · 2024: 49 · 2023: 41 · 2022: 45 · 2021: 87 · 2020: 73 · 2019: 95 · 2018: 82 · 2017: 52
- FWCI
- 94.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Chugai Pharmaceutical
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- atopic dermatitis, nemolizumab, pruritus, Eczema Area and Severity Index, body surface area involvement, treatment efficacy and safety, dose comparison, treatment discontinuation, adverse events, moderate-to-severe atopic dermatitis, adults, biologic therapy
- MeSH terms
- Adult, Dermatitis, Atopic, Edema, Female, Humans, Male, Middle Aged, Pruritus, Receptors, Interleukin, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis. https://app.cochat.ai/papers/10.1056/nejmoa1606490
- The paper
- Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., Stewart, J., & Kabashima, K. (2017). Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1606490
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.